[1] 邵海妍, 彭民金, 陈功,等. 1991-2011年中国肝癌死亡趋势的APC模型分析. 中华肿瘤防治杂志, 2016, 23:1465-1469.
[2] 董深明. CT引导下行微波消融术对肝癌患者肿瘤位置与疼痛的关系. 肝脏, 2017, 22:961-963.
[3] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版). 临床肝胆病杂志, 2011, 27:1141-1159.
[4] Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer, 2012, 118:147-156.
[5] Dueck AC, Mitchell SA, Mendoza TR, et al. Responsiveness of Items from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events. Qual Life Res, 2014, 23:37-38.
[6] 赵鹏, 郑加生, 张洪海,等. 肝动脉导管化疗栓塞联合 CT 引导精准微波消融治疗原发性肝癌的疗效及影响因素. 中华肿瘤杂志, 2016, 38:138-145.
[7] 李丽珍, 钟秋红, 黄昌辉,等. 超声引导下经皮微波消融与CT超声引导下肿瘤射频消融治疗原发性肝癌的临床比较. 中国CT和MRI杂志, 2017, 15:76-78,82.
[8] 耿利民, 寇长元, 崔杰,等. CT引导经皮微波消融联合肝动脉栓塞治疗肝癌的临床疗效. 现代肿瘤医学, 2018,26:63-66.
[9] 唐田, 古善智, 李国文,等. CT引导下微波消融治疗肝癌术后复发的疗效分析. 中国介入影像与治疗学, 2015, 12:657-660. |
